| 冯 佳,彭 敏,胡伟国.非小细胞肺癌对酪氨酸激酶抑制剂获得性耐药机制及治疗策略的研究进展[J].肿瘤学杂志,2017,23(1):6-12. |
| 非小细胞肺癌对酪氨酸激酶抑制剂获得性耐药机制及治疗策略的研究进展 |
| Research Advance on Acquired Resistance to EGFR-TKIs in Non-small Cell Lung Cancer |
| 投稿时间：2016-06-21 |
| DOI：10.11735/j.issn.1671-170X.2017.01.B002 |
|
 |
| 中文关键词: 非小细胞肺癌 表皮生长因子受体 酪氨酸激酶抑制剂 耐药 |
| 英文关键词:non-small cell lung cancer epidermal growth factor receptor tyrosine kinase inhibitor resistance |
| 基金项目: |
|
| 摘要点击次数: 1996 |
| 全文下载次数: 576 |
| 中文摘要: |
| 摘 要：表皮生长因子受体(epidermal growth factor receptor，EGFR)是非小细胞肺癌（non-small cell lung cancer，NSCLC）最常见的肿瘤驱动基因。以EGFR为靶点的酪氨酸激酶抑制剂（tyrosine kinase inhibitor，TKI）分子靶向治疗，可显著性改善携带这类基因突变的NSCLC患者的生存结局。然而，这些最初获得缓解的患者最终都会发生获得性耐药，成为进一步提高靶向药物TKI疗效的瓶颈。因此，了解TKI获得性耐药机制可指导NSCLC临床治疗。文章综述近年来NSCLC对TKI耐药机制的新进展及耐药后治疗的新策略。 |
| 英文摘要: |
| Abstract：Epidermal growth factor receptor(EGFR) is the most common tumor driven gene of non-small cell lung cancer(NSCLC). The molecular targeted therapy of EGFR tyrosine kinase inhibitor(TKI) can significantly improve survival outcome in EGFR-mutated NSCLC patients.However，the acquired resistance will eventually occur in patients with initial remission，so to further improve the effect of TKI has become a bottleneck. Therefore，understanding the mechanisms of acquired resistance to TKI may provide clue to guide TKI-targeted therapy in clinical treatment of NSCLC. This review summarizes recent progress on acquired resistance mechanisms and treatment strategies of EGFR-TKI in NSCLC． |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |